Organon & Co. (OGN)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NYSE
Market cap: $3.59B
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Latest financial period: June 30, 2026
Filed with the SEC: July 31, 2026
Estimated earnings date: November 9, 2026
Profit #517 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 65.7% | 68.8% | 69.1% | 78.6% |
Growth #1374 of 1484 companies
Payout #716 of 1484 companies
Safety #1296 of 1484 companies
Price #144 of 1484 companies
